A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of HSK46256 in Patients With Advanced Solid Tumors

Inclusion Criteria: * Age ≥18 years, voluntarily participate and provide signed informed consent, * ECOG performance status 0-1 or KPS \>60; estimated life expectancy ≥12 weeks, * Histologically or cytologically confirmed locally advanced or metastatic solid tumors, failed prior standard therapy, intolerant to standard therapy, or no available standard therapy, * Dose escalation: prior treatment with one line of non-selective PARP inhibitor allowed, * Documented HRR gene mutation, * Agree to provide tumor tissue and/or blood samples, * Fertile participants must agree to use effective contraception during study and for 3 months after last dose; negative pregnancy test for females, Exclusion Criteria: * Other malignancies within past 2 years (except adequately treated basal cell carcinoma, squamous cell carcinoma, cervical carcinoma in situ, thyroid papillary carcinoma); * Uncontrolled moderate to large pleural, pericardial, or peritoneal effusions; * Prior anticancer therapy or concomitant use of CYP3A4 strong/moderate inhibitors/inducers within protocol-specified washout periods; * Prior anticancer treatment toxicity not resolved to CTCAE ≤Grade 1 (except alopecia, skin toxicity); * Any condition affecting drug swallowing or significantly impacting drug absorption/PK; * Severe or uncontrolled cardiac disease (QTcF prolongation, significant arrhythmia, LVEF \<50%, recent MI/heart failure); * Arterial/venous thromboembolic events within 6 months deemed uncontrolled risk; * Severe/uncontrolled diabetes, hypertension, active bleeding, epilepsy, COPD, interstitial lung disease, active systemic infection; * Unstable systemic disease (severe hepatic/renal/metabolic disorders); * Prior MDS or AML diagnosis, or history of hematopoietic stem cell transplantation; * Major surgery or severe trauma within 4 weeks; * HIV positive, active hepatitis B/C, or active syphilis; * Known hypersensitivity to study drug or excipients; * Participation in another interventional trial within 4 weeks; * Pregnant or lactating women;